SEK 0.01
(7.69%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 10.72 Million SEK | -19.0% |
2022 | 13.24 Million SEK | 35.44% |
2021 | 9.77 Million SEK | 242.78% |
2020 | 2.85 Million SEK | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q1 | 2.64 Million SEK | 72.68% |
2024 Q2 | 2.04 Million SEK | -22.41% |
2024 Q3 | 2.11 Million SEK | 2.93% |
2023 FY | 10.72 Million SEK | -19.0% |
2023 Q4 | 1.53 Million SEK | -45.53% |
2023 Q2 | 3.4 Million SEK | 4.68% |
2023 Q1 | 3.24 Million SEK | -6.48% |
2023 Q3 | 2.8 Million SEK | -17.38% |
2022 Q4 | 3.47 Million SEK | 9.15% |
2022 Q3 | 3.18 Million SEK | -14.0% |
2022 Q2 | 3.7 Million SEK | 47.53% |
2022 Q1 | 2.5 Million SEK | -12.15% |
2022 FY | 13.24 Million SEK | 35.44% |
2021 Q1 | 853 Thousand SEK | -53.62% |
2021 Q4 | 2.85 Million SEK | -11.36% |
2021 FY | 9.77 Million SEK | 242.78% |
2021 Q3 | 3.22 Million SEK | 13.18% |
2021 Q2 | 2.84 Million SEK | 233.65% |
2020 Q3 | 556 Thousand SEK | 70.03% |
2020 FY | 2.85 Million SEK | 0.0% |
2020 Q2 | 327 Thousand SEK | 0.0% |
2020 Q4 | 1.83 Million SEK | 230.76% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
AroCell AB (publ) | 57.68 Million SEK | 81.407% |
Devyser Diagnostics AB (publ) | 204.6 Million SEK | 94.758% |
Immunovia AB (publ) | 291.35 Million SEK | 96.319% |
Prostatype Genomics AB (publ) | 3.22 Million SEK | -232.558% |
SenzaGen AB | 49.67 Million SEK | 78.408% |